Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation

Eur J Heart Fail. 2019 Jan;21(1):129-131. doi: 10.1002/ejhf.1356. Epub 2018 Dec 6.

Authors

Jan M Van Keer¹, Thomas Vanassche¹, Walter Droogne¹, Steffen Rex², Filip Rega³, Johan Van Cleemput¹, Peter Verhamme¹

Affiliations

¹ Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.
² Department of Anaesthesiology, University Hospitals Leuven, Leuven, Belgium.
³ Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium.

PMID: 30520546
DOI: 10.1002/ejhf.1356

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / administration & dosage*
Antithrombins / administration & dosage
Atrial Fibrillation / complications
Atrial Fibrillation / drug therapy*
Dabigatran / administration & dosage*
Dose-Response Relationship, Drug
Drug Substitution
Female
Heart Failure / complications
Heart Failure / surgery*
Heart Transplantation*
Humans
Infusions, Intravenous
Male
Middle Aged
Preoperative Period

Substances

Antibodies, Monoclonal, Humanized
Antithrombins
idarucizumab
Dabigatran